{"DataElement":{"publicId":"3916241","version":"1","preferredName":"Tyrosine Kinase Inhibitor Preparative Regimen Administered Type","preferredDefinition":"A description of tyrosine kinase inhibitor(s) administered as part of the preparative regimen.","longName":"3916223v1.0:3916236v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3916223","version":"1","preferredName":"Tyrosine Kinase Inhibitor Preparative Regimen Administered","preferredDefinition":"Substances that inhibit tyrosine kinase enzymes, involved with the transduction and processing of many extracellular and intracellular signals including cell proliferation. They have numerous applications in the prevention and treatment of cancer. (NCI)_The chemotherapy and/or radiation given to blood, marrow or cord blood transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._The act of having given something (e.g., a medication or test).","longName":"3916221v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3916221","version":"1","preferredName":"Tyrosine Kinase Inhibitor Preparative Regimen","preferredDefinition":"Substances that inhibit tyrosine kinase enzymes, involved with the transduction and processing of many extracellular and intracellular signals including cell proliferation. They have numerous applications in the prevention and treatment of cancer. (NCI):The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur.","longName":"C1967:C61155","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E84FDE31-812F-3FE9-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E84FDE31-813D-3FE9-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3916236","version":"1","preferredName":"Tyrosine Kinase Inhibitor Type","preferredDefinition":"Substances that inhibit tyrosine kinase enzymes, involved with the transduction and processing of many extracellular and intracellular signals including cell proliferation. They have numerous applications in the prevention and treatment of cancer. (NCI)_Something distinguishable as an identifiable class based on common qualities.","longName":"3916236v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Nilotinib","valueDescription":"Nilotinib","ValueMeaning":{"publicId":"2737467","version":"1","preferredName":"Nilotinib","longName":"2737467","preferredDefinition":"An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). Nilotinib interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C391-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E851088E-00DE-1C1B-E040-BB89AD4331F0","beginDate":"2013-10-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","deletedIndicator":"No"},{"value":"Imatinib mesylate","valueDescription":"Imatinib Mesylate","ValueMeaning":{"publicId":"2737465","version":"1","preferredName":"Imatinib Mesylate","longName":"2737465","preferredDefinition":"The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. It is also known as Gleevec.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib Mesylate","conceptCode":"C1687","definition":"The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C337-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E851088E-00E8-1C1B-E040-BB89AD4331F0","beginDate":"2013-10-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","deletedIndicator":"No"},{"value":"Dasatinib","valueDescription":"Dasatinib","ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E851088E-00F2-1C1B-E040-BB89AD4331F0","beginDate":"2013-10-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","deletedIndicator":"No"},{"value":"Other TKI","valueDescription":"Other Tyrosine Kinase Inhibitor","ValueMeaning":{"publicId":"5125101","version":"1","preferredName":"Other Tyrosine Kinase Inhibitor","longName":"5125101","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0CEDE4-6E88-E057-E050-BB89AD437DB7","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2C0CEDE4-6EA1-E057-E050-BB89AD437DB7","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"ONEDATA","dateModified":"2016-02-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3916235","version":"1","preferredName":"Tyrosine Kinase Inhibitor Type","preferredDefinition":"Substances that inhibit tyrosine kinase enzymes, involved with the transduction and processing of many extracellular and intracellular signals including cell proliferation. They have numerous applications in the prevention and treatment of cancer. (NCI):Something distinguishable as an identifiable class based on common qualities.","longName":"C1967:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E851088E-00B7-1C1B-E040-BB89AD4331F0","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-09","modifiedBy":"ONEDATA","dateModified":"2013-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E851088E-00C8-1C1B-E040-BB89AD4331F0","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-09","modifiedBy":"KUMMEROA","dateModified":"2016-02-18","changeDescription":". Added PV \"Other TKI\" for 2100r4. AK 2/18/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the type of tyrosine","type":"Preferred Question Text","description":"What was the type of tyrosine kinase inhibitor given for the preparative regimen?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E851088E-014D-1C1B-E040-BB89AD4331F0","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-09","modifiedBy":"KUMMEROA","dateModified":"2014-10-16","changeDescription":". Added human readable def. System generated def displayed as alt def. No version needed. AK 10/16/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}